A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders

Poullis, Andrew; Zar, Sameer; Sundaram, Krishna; Moodie, S J; Risley, Paul; Theodossi, A; Mendall, Michael A.

doi:10.1097/00042737-200204000-00013

Cited by 103 publications

(65 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quantification of canine CRP in serum can be done using several assay formats,81, 82, 83, 84, 85, 86, 87, 88 all of which have a reference interval of approximately 0–8 mg/L. A high‐sensitivity CRP (hs‐CRP) assay with improved sensitivity for lower serum CRP concentrations89, 90 currently is not routinely available in veterinary medicine 91…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

108

View full text Add to dashboard Cite

show abstract

“…Diagnosis of IBD Fecal calprotectin [69] Sensitivity: 89%-98%, specificity: 81%-91% Fecal lactoferrin [70] Sensitivity: 80%, specificity: 82% Fecal 100A12 [71] (differentiating from IBS) Sensitivity: 86%, specificity: 96% CRP [72][73][74] Sensitivity: Approximately equal 100% in CD, approximately equal 50% in UC poor specificity Distinguishing UC and CD ASCA [75] Sensitivity: 40%-50%, specificity: > 90% in CD pANCA [75] Sensitivity: 57%, specificity: 92% Escherichia coli antibodies (Anti-OmpC, Anti-I2, Anti-CBir1) [76] Sensitivity: 18%-55%, specificity: 76%-93% [76] Marker of disease activity Fecal lactoferrin [77,78] Sensitivity: 66%-80% Specificity: 60%-100% Fecal calprotectin [77,78] Sensitivity: 70%-100% Specificity: 44%-100% CRP [78] Sensitivity: 48% Specificity: 91% Assessing mucosal healing…”

Section: Application Biomarker Utilitymentioning

confidence: 99%

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Chan¹,

Wasinger²,

Leong³

2016

WJGP

View full text Add to dashboard Cite

Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease (IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD.

show abstract

“…Najczęściej stosowanym wykładnikiem stanu zapalnego jest stężenie CRP w surowicy [14,15]. Odczyn Biernackiego (OB) jest wskaźnikiem mniej specyficznym, może jednak być przydatny przy ocenie pacjentów z ChLC [16].…”

Section: Mówi Się Wówczas O Nieokreślonym Zapaleniu Okrężni-cy (Indetunclassified

Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

Łodyga¹,

Eder²,

Bartnik³

et al. 2012

View full text Add to dashboard Cite

A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders

Abstract: A new, highly sensitive assay for CRP may help to distinguish FBD from IBD.

Cited by 103 publications

References 4 publications

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

Contact Info

Product

Resources

About